CLONIDINE TREATMENT FOR PTSD IN CHILDREN

这是一个香农奖提供部分支持的研究 项目不属于指定机构的资助范围，但 在优秀的边缘。香农奖旨在提供 支持测试方法的可行性;支持进一步测试 和完善研究技术;对现有的 数据集;或进行离散项目，以证明PI 研究能力或导致额外的重量已经优秀 应用程序.下面的应用程序是从原始文件 由主要经销商提交。 虽然创伤会对心理和生理产生深远的影响 在发育中的孩子身上，没有双盲安慰剂， 治疗创伤后应激障碍的对照药物试验 儿童的紊乱。目前的建议是一个双盲，安慰剂- 可乐定治疗儿童创伤后应激障碍的对照试验 可乐定是一种α 2-肾上腺素能激动剂，通过降低 去甲肾上腺素能传递许多临床前和临床 描述性、心理生理学、神经内分泌学和药理学 挑战研究指出，交感神经系统的反应性增加， 在成年人的“压力”条件下可检测到的神经系统 和患有创伤后应激障碍的儿童去甲肾上腺素能系统的敏感性增加 似乎会让人处于高度警觉的睡眠状态 被剥夺且有时激动的状态可能会随着时间的推移而恶化。是 假设用可乐定治疗的创伤儿童 与安慰剂组相比，PTSD症状的减轻程度更大。 此外，假设基线治疗前水平 将进行儿茶酚胺、声惊吓和心血管测量， 与治疗结果显著相关。最后，预测 随着时间的推移， 减少了创伤后应激障碍，声音惊吓和心血管 措施这些假设将在30名创伤患者的试验中进行测试。 在两个治疗组（积极治疗组和 安慰剂）。希望对儿童进行早期药物干预 创伤后应激障碍将有助于防止长期后果的混乱 兴奋

THIS IS A SHANNON AWARD PROVIDING PARTIAL SUPPORT FOR THE RESEARCH PROJECTS THAT FALL SHORT OF THE ASSIGNED INSTITUTE'S FUNDING RANGE BUT ARE IN THE MARGIN OF EXCELLENCE. THE SHANNON AWARD IS INTENDED TO PROVIDE SUPPORT TO TEST THE FEASIBILITY OF THE APPROACH; DEVELOP FURTHER TESTS AND REFINE RESEARCH TECHNIQUES; PERFORM SECONDARY ANALYSIS OF AVAILABLE DATA SETS; OR CONDUCT DISCRETE PROJECTS THAT CAN DEMONSTRATE THE PI'S RESEARCH CAPABILITIES OR LEAD ADDITIONAL WEIGHT TO AN ALREADY MERITORIOUS APPLICATION. THE APPLICATION BELOW IS TAKEN FROM THE ORIGINAL DOCUMENT SUBMITTED BY THE PRINCIPAL INVESTIGATOR. Although trauma can have profound psychological and physiological effects on the developing child, there have been no double-blind placebo- controlled pharmacologic trials for the treatment of posttraumatic stress disorder in children. The present proposal is a double-blind, placebo- controlled trial of clonidine for the treatment of PTSD in children. Clonidine is an alpha2-adrenergic agonist that acts by decreasing noradrenergic transmission. Numerous preclinical and clinical descriptive, psychophysiologic, neuroendocrine and pharmacologic challenge studies point to an increased responsivity of the sympathetic nervous system that is detectable under conditions of "stress" in adults and children with PTSD. Increased sensitivity of the noradrenergic system appears to leave the individual in a hyperaroused, vigilant, sleep- deprived and at times agitated state that may worsen over time. It is hypothesized that traumatized children treated with clonidine will have a greater reduction in PTSD symptoms than children treated with placebo. Further, it is hypothesized that baseline pre-treatment levels of catecholamines, acoustic startle and cardiovascular measurements will be significantly correlated with treatment outcome. Finally, it is predicted that decreases in catecholamine activity over time will be associated with decreased PTSD symptomatology, acoustic startle and cardiovascular measures. These hypotheses will be tested in a trial of 30 traumatized children with PTSD in each of the two treatment groups (active and placebo). It is hoped that early pharmacologic intervention in children with PTSD will help to prevent the long-term consequences of disordered arousal.